BIOTRONIK

284 articles about BIOTRONIK

• Aziyo Announces CanGaroo Strategic Co-Distribution Agreement with BIOTRONIK US

  4/19/2018

  Aziyo Biologics, Inc., a fully integrated regenerative medicine company, today announced that it has entered into a US co-distribution agreement for its CanGaroo® Bio Envelope with BIOTRONIK, Inc., a global leader in cardio- and endovascular medical technology.

• BIOTRONIK Release: CASTLE-AF Results Published in the New England Journal of Medicine, Showing Mortality Reduction for Heart Failure Patients

  2/1/2018

  This reduction was observed when compared to patients treated with the pharmacological therapy recommended by current guidelines.

• LINC 2018: BIOTRONIK Presents Excellent 12-Month Data on More Than 1000 Patients

  1/31/2018

  During a well-attended BIOTRONIK-sponsored symposium chaired by Dr. Jos van den Berg, Professor of Interventional Radiology, Ospedale Regionale di Lugano, Switzerland, panelists demonstrated that reducing metal burden in superficial femoral artery therapy could effectively reduce restenosis rates.

• Orsiro Coronary Drug-Eluting Stent Receives Market Approval in Japan

  1/22/2018

  BIOTRONIK announced today market approval for its Orsiro1 coronary drug-eluting stent by the Japanese Ministry of Health.

• TCT 2017: BIOTRONIK's Orsiro Drug-Eluting Stent Shows Low Five-Year Event Rates in BIOFLOW-II RCT and BIOFLOW-III Registry

  11/2/2017

  Data from the BIOFLOW-II randomized controlled trial was presented in a poster session by Dr. Ton Slagboom, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands, showing a target leisure failure (TLF) rate of 10.4 percent in the Orsiro group and 12.7 percent in the Xience2 study arm at 60 months (p=0.4728).

• BIOTRONIK Release: TCT 2017: Magmaris Resorbable Magnesium Scaffold (RMS) Continues to Show No Instances of Scaffold Thrombosis

  11/1/2017

  Data presented during the TCT congress on BIOTRONIK’s Magmaris1 RMS provide further evidence on its continued safety and efficacy.

• TCT 2017: BIOTRONIK Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice

  10/31/2017

  Data presented at the BIOTRONIK-sponsored symposium on the Orsiro1 drug-eluting stent (DES) demonstrate why Orsiro is gaining prominence in the crowded DES market.

• BIOTRONIK CLS Technology Shown To Reduce Fainting In Syncope Patients By Seven-Fold

  10/4/2017

• CIRSE 2017: BIOTRONIK Studies Demonstrate Efficacy Of Minimizing Metal Burden In SFA Therapy

  9/18/2017

• European Heart Rhythm Association And BIOTRONIK Mark Ten Years Of Collaboration With EHRA White Book 2017 Analysis

  8/29/2017

• ESC Congress 2017: BIOTRONIK's Orsiro Drug-Eluting Stent Outperforms Xience In BIOFLOW-V Trial

  8/29/2017

• BIOTRONIK Release: CASTLE-AF Study Results Indicate Catheter Ablation Of Atrial Fibrillation As First-Line Treatment For Heart Failure Patients

  8/28/2017

• Late-Breaking BIOTRONIK Study Results To Be Presented At ESC Congress 2017

  8/24/2017

• Getinge Announces Full U.S. Availability Of Pulsar-18 Self-Expanding Stent From BIOTRONIK For Patients With Peripheral Artery Disease

  8/22/2017

• BIOTRONIK US Launches Smallest MR Conditional Quadripolar Cardiac Resynchronization Therapy Pacemaker

  8/21/2017

• Fewer Leads, Fewer Complications: BIOTRONIK US Launches Proven DX Technology For Heart Failure Patients

  7/19/2017

• BIOTRONIK’s New Quadripolar Crt-P With More Pacing Options Now Available In Japan

  7/11/2017

• BIOTRONIK Release: Europace-Cardiostim 2017: Challenges And New Opportunities In Heart Failure Management

  6/19/2017

• BIOTRONIK Receives CE Mark For 3 Tesla Full-Body Mris With Newest Pacemakers

  6/13/2017

• BIOTRONIK Launches Edora Pacemaker Series With MRI AutoDetect Technology

  6/7/2017